A popular GLP-1 provider just made its weight loss medications cheaper - USA Today
Mochi Health just lowered the cost of its compounded GLP-1 medications while adding a new lab-testing service designed to help patients track key health markers during treatment.
The telehealth platform recently announced a new dose-based pricing structure for compounded semaglutide and compounded tirzepatide, along with the launch of Mochi Labs, an integrated blood-testing service.
For people exploring GLP-1 weight-loss treatment, the updates address two common concerns: affordability and ongoing medical monitoring.
Under Mochi Health's new pricing model, compounded semaglutide now starts at $60 per month, while compounded tirzepatide starts at $90 per month.
The company says pricing is now tied to dosage levels, which could benefit many new patients who begin treatment on lower introductory doses before gradually increasing over time.
According to Mochi Health, no dose costs more than previous pricing, and many options are now available at lower monthly rates.
Patients who enroll begin with a live, 30-minute virtual appointment with a licensed healthcare provider before receiving any prescription recommendation. Membership plans start at $39 for the first month and include unlimited provider visits, direct messaging and access to healthcare professionals. Medication costs are separate from membership fees.
Alongside the pricing change, Mochi Health launched Mochi Labs, a new service that allows patients to order and manage bloodwork through the same platform used for their care.
Patients can request testing through the Mochi portal, visit a participating laboratory location and receive results within their account, according to the company.
Additional testing options include GLP-1 monitoring panels, women's health panels, men's health panels and broader health assessments.
The company says providers can use lab results to help monitor factors such as metabolic health, thyroid function and nutritional markers throughout treatment and make adjustments when appropriate.
As GLP-1 medications continue to gain popularity for weight management, many patients have been looking for options that balance cost with clinical oversight.
Mochi Health's latest updates reflect the growing demand for both. Lower entry-level pricing may make treatment more accessible for patients starting their weight loss journey, while integrated lab testing could provide additional insight into how treatment is affecting their overall health.
The laboratory service is available in most states, though Mochi Health says it is not currently offered in New York, New Jersey, Rhode Island or Hawaii.
For now, compounded semaglutide and compounded tirzepatide remain the company's primary treatment offerings.
Editor's note: Compounded semaglutide and compounded tirzepatide are not FDA-approved products. Brand-name GLP-1 medications may be referenced for context but are not substitutes for compounded medications.
USA TODAY Shopping will be covering all the best deals and drops, so be sure to sign up for text alerts, check us out on Flipboard, follow us on TikTok, sign up for our newsletter and follow us on Instagram to stay updated!
This story was produced with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the review, editing and publishing process. Learn more at cm.usatoday.com/ethical-conduct.
Our editors independently choose our recommendations. Some content is produced with paid support from a third party, however our editorial decisions remain independent. If you buy through our links, the USA TODAY Network may earn a commission. Prices and availability may change.
